



Correction to: Assessing Case Fatality on Cases of Thrombosis with Concurrent Thrombocytopenia Following COVID-19 Vaccine AstraZeneca (Vaxzevria) in the United Kingdom: A Review of Spontaneously Reported Data

Samantha Lane^{1,2} · Saad Shakir^{1,2}

Published online: 3 September 2022
© The Author(s) 2022

Correction to: Drug Safety (2022) 45:1003–1008
<https://doi.org/10.1007/s40264-022-01217-9>

In Table 2 of this article, the number of reports for the 60–69 years age group should be 62 instead of 11.

The corrected Table 2 is given below.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

The original article can be found online at <https://doi.org/10.1007/s40264-022-01217-9>.

✉ Samantha Lane
Samantha.Lane@dsru.org

¹ Institute of Pharmacovigilance Sciences, Drug Safety Research Unit, Bursledon Hall, Blundell Lane, Southampton SO31 1AA, UK

² School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, UK

Table 2 Cumulative case fatality of thrombosis with thrombocytopenia events reported to the Yellow Card Scheme to 25 May 2022

Age group (years)	Number of reported TTS events submitted to Yellow Card Scheme	Cumulative case fatality of TTS (%)	Lower 95% CI	Upper 95% CI
18–29	31	22.58	9.59	41.10
30–39	49	20.41	10.24	34.34
40–49	111	13.51	7.77	21.31
50–59	108	20.37	13.24	29.20
60–69	62	17.74	9.20	29.53
70–79	40	17.50	7.34	32.78
80–89	6	50.00	11.81	88.19
90+	2	50.00	1.26	98.74
Not specified	34	14.71	4.95	31.06

TTS thrombotic thrombocytopenia syndrome, *CI* confidence interval